Pharma and Trump find 'areas of common ground' in meeting

1 February 2017

How new US President Donald Trump’s meeting with pharma bosses went on Tuesday was always going to be a matter of interpretation, with the industry, the new administration and its critics all likely to put their own spin on the discussions.

But there seems to be a general consensus in reports of the proceedings and subsequent statements that Mr Trump’s approach might be more favorable to pharma than the industry feared when he said that drugmakers were “getting away with murder” and hinted at potential interventions to lower prices.

"The US drug companies have produced extraordinary results for our country but the pricing has been astronomical for our country"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK